Hodgkin’s lymphoma can usually be cured. Treatment for Hodgkin’s lymphoma depends on the stage. Stages are used to describe how much the cancer has worsened or spread.

Stages and Treatments

Treatments and stages for Hodgkin’s lymphoma are:

Stage I – The lymphoma is only in one lymph node region or a single organ.

Treatment for Stage I Hodgkin’s lymphoma may include:

  • Chemotherapy
  • Corticosteroids
  • Radiation therapy
  • Stem cell transplant
  • Immunotherapy

Stage II – The lymphoma is in two lymph node regions or has spread to one organ and its nearly lymph nodes. The tumor is either above or below the diaphragm.

Treatment for Stage II Hodgkin’s lymphoma may include:

  • Chemotherapy
  • Corticosteroids
  • Radiation therapy
  • Targeted therapy
  • Stem cell transplant
  • Immunotherapy

Stage III – The lymphoma has spread to the lymph nodes both above and below the diaphragm. The lymphoma may have spread to tissue near an organ, lymph nodes, or the spleen.

Treatment for Stage III Hodgkin’s lymphoma may include:

  • Chemotherapy
  • Corticosteroids
  • Radiation therapy
  • Targeted therapy
  • Stem cell transplant
  • Immunotherapy

Stage IV – In this advanced stage of lymphoma, the cancer has spread to several areas of one or more organs or tissues. The lymphoma affects the lymph nodes and other areas of the body, such as the lungs, liver, or bone.

Treatment for Stage IV Hodgkin’s lymphoma may include:

  • Chemotherapy
  • Corticosteroids
  • Radiation therapy
  • Targeted therapy
  • Stem cell transplant
  • Immunotherapy

Types of Treatments

Treatments for Hodgkin’s lymphoma include:

  • Chemotherapy
  • Corticosteroids
  • Radiation therapy
  • Targeted therapy
  • Immunotherapy
  • Stem cell transplant

Chemotherapy – Chemotherapy uses drugs to kill cancer cells. Chemotherapy may be given by pill or directly into vein. Chemotherapy is often used in combination with radiation therapy or other drugs, such as corticosteroids, for the treatment of Hodgkin’s lymphoma.

Chemotherapy drugs combined with corticosteroids used for Hodgkin’s lymphoma include:

  • Combination regimen of nitrogen mustard, vincristine, procarbazine, and prednisone
  • Combination regimen of doxorubicin, bleomycin, vinblastine, and dacarbazine,
  • Combination regimen of nitrogen mustard, vincristine, procarbazine, bleomycin, Adriamycin, and prednisone
  • Combination regimen chlorambucil, vinblastine, procarbazine, and prednisone

Radiation therapy – Radiation therapy uses high-energy radiation, such as X-Rays or protons, to kill cancer cells. Radiation therapy is often used in combination with chemotherapy for the treatment of Hodgkin’s lymphoma.

Targeted therapy – Targeted therapy uses drugs that stop cancer cells from growing. Targeted therapy drugs for the treatment of Hodgkin’s lymphoma include brentuximab and rituximab.

Immunotherapy (Biological therapy) – Immunotherapy uses the body’s immune system, or the body’s natural defenses, to kill cancer. Immunotherapy drugs for the treatment of Hodgkin’s lymphoma include:

  • Brentuximab vedotin
  • Nivolumab
  • Pembrolizumab

Stem cell transplant – This treatment for Hodgkin’s lymphoma may be used to replace diseased bone marrow with healthy stem cells.

Palliative Care

In addition to standard treatments, patients with cancer may also be treated with palliative care. Palliative care is used to relieve pain and other symptoms to make a patient more comfortable.

New, Experimental Treatment

The drug, leukine, was approved by the FDA (2018) for the treatment of Hodgkin’s lymphoma.

Long-Term Follow Up

Ongoing, long-term follow-up is an essential part of the treatment for patients with Hodgkin’s lymphoma because the cancer can reoccur even after it has been treated.

Sources

This content was written by the MediFind Medical Team. Last updated: 6/9/2022

Medications for Hodgkin Lymphoma

These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Hodgkin Lymphoma.

Found 9 Approved Drugs for Hodgkin Lymphoma

DOXOrubicin

Brand Names
Doxil, Adriamycin

DOXOrubicin

Brand Names
Doxil, Adriamycin
Doxorubicin is an anthracycline topoisomerase II inhibitor indicated: as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer.

Bleomycin

Generic Name
Bleomycin

Bleomycin

Generic Name
Bleomycin
Bleomycin for Injection, USP should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to Bleomycin for Injection, USP is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for Injection, USP has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for Injection, USP is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions.

Dacarbazine

Generic Name
Dacarbazine

Dacarbazine

Generic Name
Dacarbazine
Dacarbazine for Injection is indicated in the treatment of metastatic malignant melanoma. In addition, Dacarbazine for Injection is also indicated for Hodgkin’s disease as a second-line therapy when used in combination with other effective agents.

Adcetris

Generic Name
Brentuximab Vedotin

Adcetris

Generic Name
Brentuximab Vedotin
ADCETRIS is a CD30-directed antibody and microtubule inhibitor conjugate indicated for treatment of: Adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vinblastine, and dacarbazine.

Nivolumab

Brand Names
Opdivo, Opdualag, Opdivo QVANTIG

Nivolumab

Brand Names
Opdivo, Opdualag, Opdivo QVANTIG
OPDIVO QVANTIG is a combination of nivolumab, a programmed death receptor-1 (PD-1)-blocking antibody, and hyaluronidase, an endoglycosidase, indicated for the treatment of: Renal Cell Carcinoma (RCC) adult patients with intermediate or poor risk advanced RCC, as a first-line treatment following combination treatment with intravenous nivolumab and ipilimumab.
Showing 1-5 of 9
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances